When used to treat BRAF600-mutant metastatic non-small cell lung cancer, dabrafenib, an inhibitor of BRAF, and trametinib, an inhibitor of MEK, had an objective response rate (ORR) of 64% [66]. Here, MAP2K7 is linked to non-small cell lung carcinoma.